Abstract 1953P
Background
The diversity of clinical and pathological characteristics of soft tissue sarcoma (STS) presents a challenge for the prediction of prognosis. Recently, pretreatment inflammatory markers have gained interest as predictive factors for survival in cancer patients. The aim of this study is to evaluate inflammatory markers as a predictive biomarker for early recurrence in STS.
Methods
118 patients with primary, localized soft tissue sarcoma were retrospectively reviewed for early recurrence. Early recurrence was defined as a disease relapse (local or distant) within the first year after diagnosis. Pretreatment inflammatory markers including leukocytes, interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and other variables including tumor grade, tumor Departmenth, location, size, and the presence of tumor necrosis on imaging were analyzed for their association with early recurrence. Survival data was analyzed using Log-rank test and Cox regression to identify prognostic factors for early recurrence.
Results
Pretreatment IL-6 elevation was associated with higher tumor grade, increased size, and necrosis on imaging. Elevated CRP was associated with higher tumor grade, NLR and PLR with tumor Departmenth, and PLR with tumor location. Early recurrences were found in 23 of 118 patients (19.5%): 7 local, 15 distant recurrences and 1 with both manifestations. Univariate analysis revealed that tumor grade (low vs high, p = 0.008), tumor Departmenth (superficial vs deep, p = 0.005), and IL-6 level (< 7 vs ≥ 7 ng/L, p = 0.012) were significantly associated with early recurrence; other inflammatory markers including leukocytes, CRP, NLR and PLR were not. Multivariate analysis did not reveal independent risk factors associated with the development of early recurrences in STS, although the number of cases were low.
Conclusions
Early recurrences in STS are not only associated with higher grade and deeper tumors, but also with increased plasma levels of IL-6.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W.T.A. Van Der Graaf: Financial Interests, Institutional, Advisory Board: PTC Therapeutics, Agenus, SpringworksTx; Financial Interests, Institutional, Local PI, Clinical study: Springworks, Boehringer Ingelheim; Financial Interests, Institutional, Research Grant, IIS: Lilly; Financial Interests, Institutional, Local PI, Clinical Study: AYALA; Non-Financial Interests, Member of Board of Directors, President: EORTC; Non-Financial Interests, Member of Board of Directors: European Cancer Organisation; Non-Financial Interests, Member of Board of Directors, Chair: Dutch Sarcoma Group, Dutch AYA 'Young and Cancer' Care Network. D. Van Den Broek: Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Expert Testimony: Roche; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Funding: ZonMW, Delfi Diagnostics. N. Steeghs: Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim, Ellipses Pharma, Luszana; Financial Interests, Personal, Advisory Board: GSK, Incyte; Financial Interests, Institutional, Local PI: AbbVie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, BMS, Cantargia, CellCentric, Cogent Biosciences, Crescendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GSK, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer, Deciphera, GSK, Lixte, Merck, Novartis, Pfizer, Roche. W. Van Houdt: Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Advisory Board: Belpharma, Sanofi, MSD; Financial Interests, Personal, Other, travel grant: Novartis; Financial Interests, Institutional, Local PI: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15